INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.

EyePoint shares fell $9.88, or 66.98%, to $4.87 on August 17, 2026 after its pivotal Phase 3 LUGANO trial for DURAVYU in wet age-related macular degeneration failed to meet the primary visual-acuity endpoint across the full dataset versus Regeneron’s 2 mg Eylea. Pomerantz LLP is investigating potential securities-fraud and other claims against EyePoint and certain officers or directors, adding legal risk following the clinical setback.

Analysis

The legal solicitation itself is not a new fundamental catalyst; the investable issue is that EYPT’s valuation has shifted from a platform/launch option to a binary clinical salvage and financing case. A failed primary comparison against standard-of-care materially weakens pricing power and physician adoption even if a subset analysis is later highlighted. With the equity already impaired, cash runway, remaining pivotal-study design, and FDA meeting feedback—not litigation headlines—will determine whether further dilution becomes the dominant downside over the next 3-9 months.

REGN gains modestly at the margin because an unsuccessful long-duration competitor reduces the near-term risk of share loss and rebate pressure in wet AMD. The more important read-through is for other sustained-delivery retinal programs: investors should demand clear noninferiority margins, rescue-treatment rates, and durability-adjusted safety before assigning premium peak-sales multiples. This is a negative sentiment spillover rather than a direct earnings driver for REGN.

Consensus may overreact to a plaintiff-firm announcement as evidence of incremental liability. Such notices commonly follow large drawdowns and do not establish misconduct, while damages/recovery timing would be measured in years. Conversely, the stock can remain structurally weak despite litigation proving immaterial if management cannot show a credible regulatory path or fund operations without highly dilutive capital; avoid treating the post-collapse price as evidence of a floor.

Key Decisions for Investors

• No new EYPT long on the litigation notice. Maintain an avoid/underweight stance for 1-3 months pending disclosure of cash runway, next-study protocol, and FDA interaction; a financing announced at a steep discount or a narrowed/no viable regulatory path would falsify any stabilization thesis.
• For biotech books requiring exposure, express the competitive read-through as a modest long REGN versus short XBI hedge over 3-6 months rather than a standalone REGN trade; upside is limited because wet-AMD economics are not a primary driver of REGN’s consolidated earnings.
• Monitor EYPT for a tactical event-driven long only if management provides independently credible evidence that a predefined subgroup supports a registrational path and the stock trades below net cash after adjusting for expected trial spend. Without those data, risk/reward remains unknowable rather than attractive.
• Screen retinal-drug peers for upcoming data and reduce positions where valuation assumes durable efficacy alone; require disclosure on injection burden, rescue rates, inflammation, and comparator performance. The relevant catalyst window is each program’s next clinical update, not the legal process.